1 min read
Add as a preferred source on GoogleLatigo Biotherapeutics’ Q3 Loss Per Share Beats Estimate by $0.12
The company expects $401 million in cash and cash equivalents to fund operations into 2029.
Latigo Biotherapeutics, Inc. (LTGO) posted a third-quarter GAAP loss of $0.55 per share, beating estimates by $0.12. The company expects its $401 million in cash and cash equivalents to fund operations into 2029.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.